Pre-clinical studies examining potential toxicities are usually performed in the absence of cancer, and therefore do not replicate the potentially important interactions between VEGFI therapy and tumour-related VEGF secretions, inflammation or oxidative stress. The gene discussed is VEGFA; the disease is neoplasm.